Status:
COMPLETED
High-Dose Vitamin C Treatment in Critically Ill COVID-19 Patients
Lead Sponsor:
Sisli Hamidiye Etfal Training and Research Hospital
Conditions:
Respiratory Distress Syndrome, Adult
Covid19
Eligibility:
All Genders
18-99 years
Brief Summary
Acute respiratory failure due to COVİD-19 pneumonia has poor prognosis and high mortality . Both the lack of an effective antiviral treatment and the low level evidence of the recommendations presente...
Detailed Description
SARS-CoV-2 causes tissue damage in the endothelium and epithelium, increased vascular permeability and increased plasma levels of IL-6, IL-2, IL-7, IL-10 causing interstitial fibrosis in the lung is c...
Eligibility Criteria
Inclusion
- Hospitalized with diagnosis of COVID-19, diagnosis confirmed by PCR test
- pneumonia due to COVID-19 was diagnosed with clinical and radiological findings
- Patients who developed acute respiratory failure (PaO2 / FiO2 300 despite the use of 6 l / min reservoir mask) caused by COVID-19 pneumonia
- Older than 18 year
Exclusion
- Renal failure
- Hepatic failure
- End-stage malignity
- Primary lung disease (lung cancer, cardio-pulmonary edema)
- Patients who treated with tocilizumab
- Presence of diabetic ketoacidosis, use of insulin infusion, or frequent need for point-of-care glucose monitoring (\>6 times/24 hour period) as determined by treating physician
- Active kidney stone
- patients with hospitalization in ICU less than 96 hours
Key Trial Info
Start Date :
January 16 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 10 2021
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT04710329
Start Date
January 16 2021
End Date
February 10 2021
Last Update
February 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sisli etfal training and resource hospital
Şişli, Istanbul, Turkey (Türkiye), 34376